UBS ETFIn order to proceed, you must confirm that you are a qualified or institutional investor based in the United Kingdom.
UBS ETF (IE) Global Gender Equality UCITS ETF (USD) A-dis
Select a fund for comparison
Name of fund
UBS (Irl) ETF plc – Global Gender Equality UCITS ETF
UBS (Irl) ETF plc – Global Gender Equality UCITS ETF (USD) A-dis
Solactive Equileap Global Gender Equality 100 Leaders Index
Currency of share class
Accounting year end
Physical (Full replicated)
twice a year
- The fund generally invests in the Solactive Equileap Global Gender Equality 100 Leaders Net Total Return Index. The relative weightings of the companies correspond to their weightings in the index.
- The investment objective is to replicate the price and return performance of the Solactive Equileap Global Gender Equality 100 Leaders Net Total Return Index net of fees. The stock exchange price may differ from the net asset value.
- The fund is passively managed.
Management fee p.a.
Flat fee p.a.
Total expense ratio (TER) p.a.1)
- The Index has been designed to track the top companies leading the field internationally in terms of gender equality. In-depth gender equality screening as defined by Equileap is carried out. Companies which derive the majority of their revenues from the controversial weapons, gambling, tobacco or coal extraction and power generation industries are excluded. Also companies which are not complaint with the UNGC and OECD guidelines are not considered.
Please consider that this performance comparison tool serves for illustration purposes only as it allows to compare any UBS ETF regardless its fund characteristics, investment objectives. Please note that certain comparisons might be insignificant or misleading due to markets, currencies, sectors or risk exposures that might not be comparable. Neither UBS AG / UBS Asset Management (UK) Ltd nor any of its affiliates, its directors, employees or agents accepts any liability for any loss or damage arising out of the use of this tool.
Disclaimer: Past performance is not a guide to future performance. The value of investments and the income from them may go down as well as up and are not guaranteed. Investors may not get back the amount originally invested. Changes in rates of exchange may cause the value of this investment to fluctuate. Investments in less developed markets may be more volatile than investments in more established markets. Synthetic replicated ETFS will use derivatives as part of their investment capabilities. These instruments carry a material level of risk and the Fund could potentially experience higher levels of volatility should the market move against them. In order to trade in derivative instruments we enter into an agreement with various counterparties. Whilst we assess the credit worthiness of each counterparty we enter into an agreement with, the Fund is at risk if that counterparty does not fulfil its obligations under the agreement. Any collateral paid by the Fund may not be returned, nor may any payments due to the Fund be made. Some of the markets in which the Fund may effect derivative transactions are “over-the-counter” or “interdealer” markets, which may be illiquid and are sometimes subject to larger spreads than exchange-traded derivative transactions. The participants in such markets are typically not subject to credit evaluation and regulatory oversight, which would be the case with members of “exchange-based” markets. This exposes the Fund to the risk that a counterparty will not settle a transaction in accordance with its terms and conditions because of a credit or liquidity problem with the counterparty. Delays in settlement may also result from disputes over the terms of the contract (whether or not bona fide) since such markets may lack the established rules and procedures for swift settlement of disputes among market participants found in "exchange-based” markets. These factors may cause the Fund to suffer a loss due to adverse market movements while replacement transactions are executed or otherwise. The UBS ETF Sicav is a recognised scheme under section 264 of the Financial Services and Markets Act 2000. It does seek UK Reporting Fund Status. The protections offered by the UK’s regulatory system, and compensation under the Financial Services Compensation Scheme, will not be available. The information contained in this document should not be considered a recommendation to purchase or sell any particular security and the opinions expressed are those of UBS Asset Management and are subject to change without notice. This material supports the presentation(s) given. It is not intended to be read in isolation and may not provide a full explanation of all the topics that were presented and discussed. Care has been taken to ensure the accuracy of the content, but no responsibility is accepted for any errors or omissions. This document is a marketing communication. Any market or investment views expressed are not intended to be investment research. The document has not been prepared in line with the FCA requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. UBS funds under Luxembourg law. Prospectuses, simplified prospectuses, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available free of charge from UBS Fund Services (Luxembourg) S.A., P.O. Box 91, L-2010 Luxembourg or from UBS Asset Management (UK) Ltd, 21 Lombard Street, London, EC4R 9AH. The MSCI indexes are the exclusive property of MSCI Inc. ("MSCI"). MSCI and the MSCI index names are service mark(s) of MSCI or its affiliates and have been licensed for use for certain purposes by UBS AG ("UBS"). The products referred to herein are not sponsored, endorsed, or promoted by MSCI, and MSCI bears no liability with respect to any such product. The full prospectus of the UBS ETF Sicav contains a more detailed description of the limited relationship MSCI has with UBS and any related products. No purchaser, seller or holder of this product, or any other person or entity, should use or refer to any MSCI trade name, trademark or service mark to sponsor, endorse, market or promote this product without first contacting MSCI to determine whether MSCI's permission is required. Under no circumstances may any person or entity claim any affiliation with MSCI without the prior written permission of MSCI. Before investing in a product please read the latest simplified prospectus or prospectus carefully and thoroughly. Units of UBS funds mentioned herein may not be offered, sold or delivered in the United States. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. UBS Asset Management (UK) Ltd is a subsidiary of UBS AG. Registered in England. UBS Asset Management (UK) Ltd and UBS Asset Management Funds Ltd are authorised and regulated by the Financial Conduct Authority. UBS Asset Management Life Ltd is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. Telephone calls may be recorded. © UBS 2017. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.